| 935666-88-9 | Azd-1480 | AZD1480 抑制剂 | C14H14ClFN8 | 348.765963077545 |
| 1204144-28-4 | AZD1208 | AZD1208 | C21H21N3O2S | 379.475343465805 |
| 941678-49-5 | Ruxolitinib | 芦可替尼 | C17H18N6 | 306.365022182465 |
| 941685-37-6 | Ruxolitinib (S enantiomer) | 环丙基[4-[3-(1H-咪唑-5-基)丙氧基]苯 | C17H18N6 | 306.365022182465 |
| 1025065-69-3 | SGI-1776 free base | 左氧氟沙星-d8 | C20H22F3N5O | 405.416794300079 |
| 501919-59-1 | NSC 74859 | NSC 74859 | C16H15NO7S | 365.357803583145 |
| 19983-44-9 | Stattic | 盐酸萘替芬 | C8H5NO4S | 211.194600820541 |
| 936091-14-4 | TG101209 | N-(1,1-二甲基乙基)-3-[[5-甲基-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基]苯磺酰胺 | C26H35N7O2S | 509.666803598404 |
| 438190-29-5 | (Z)-SMI-4a | Pim1抑制剂SMI-4a | C11H6F3NO2S | 273.231051921844 |
| 936091-26-8 | Fedratinib | N-(1,1-二甲基乙基)-3-[[5-甲基-2-[[4-[2-(1-吡咯烷基)乙氧基]苯基]氨基]-4-嘧啶基]氨基]苯磺酰胺 | C27H36N6O3S | 524.678144454956 |
| 211555-04-3 | WHI-P154 | WHI-P154 抑制剂 | C16H14BrN3O3 | 376.204662799835 |
| 857064-38-1 | WP1066 | WP1066 抑制剂 | C17H14BrN3O | 356.216562747955 |
| 1021868-92-7 | ZM39923 hydrochloride | ZM39923盐酸盐 | C23H26ClNO | 367.911645412445 |
| 945755-56-6 | XL019 | XL019 抑制剂 | C25H28N6O2 | 444.528824806213 |
| 1202916-90-2 | CX-6258 | (3E)-5-氯-3-[[5-[3-[(六氢-4-甲基-1H-14-二氮杂革-1-基)羰基]苯基]-2-呋喃]亚甲基]-1,3-二氢-2H-吲哚-2-酮 | C26H24ClN3O3 | 461.940065383911 |
| 1257704-57-6 | CEP-33779 | CEP-33779 | C24H26N6O2S | 462.567243099213 |
| 1007207-67-1 | Izorlisib | CH5132799 抑制剂 | C15H19N7O3S | 377.421460390091 |
| 1187594-09-7 | Baricitinib | 巴瑞替尼 | C16H17N7O2S | 371.416880369186 |
| 540737-29-9 | Tofacitinib citrate | 枸橼酸托法替尼 | C22H28N6O8 | 504.493124961853 |
| 1229236-86-5 | Gandotinib | 盐酸巴多昔芬 | C23H25ClFN7O | 469.942306280136 |
| 905586-69-8 | AZ960 | 5-氟-2-[[(1S)-1-(4-氟苯基)乙基]氨基]-6-[(5-甲基-1H-吡唑-3-基)氨基]-3-吡啶腈 | C18H16F2N6 | 354.356649398804 |
